Arvinas, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Investigation Details

On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio. Management also announced it was initiating cost reductions, including cutting approximately one-third of its workforce.

Following this news, ARVN’s stock price fell by $2.39 per share, or approximately 25% to close at $7.23 per share.